The investigators compared long-term refractive and biometric outcomes in children with retinopathy of prematurity who received two different anti-vascular endothelial growth factor agents.
Purpose: To compare refractive and biometric outcomes in patients with type 1 retinopathy of prematurity (ROP) treated with intravitreal injection of Ranibizumab (IVR), versus bevacizumab (IVB), at a corrected age of 3 years. Methods: A retrospective case series compared cycloplegic refractive statuses and biometric statuses in patients who received either IVR or IVB for Type 1 ROP, from April 2011 to April 2014. Comparison of refractive errors and biometric findings between the two groups was performmed and multivariate analysis of possible factors contributive to visual acuity was also performmed
Study Type
OBSERVATIONAL
Enrollment
35
intravitreal injection of bevacizumab
intravitreal injection of ranibizumab
spherical equivalent
spherical power + half of cylinder power
Time frame: at corrected age of 3 year-old
astigmatism
in cylinder power
Time frame: at corrected age of 3 year-old
axial length
axial length in mm
Time frame: at corrected age of 3 year-old
cornea radius
cornea radius in mm
Time frame: at corrected age of 3 year-old
anterior chamber depth
anterior chamber depth in mm
Time frame: at corrected age of 3 year-old
lens thickness
lens thickness in mm
Time frame: at corrected age of 3 year-old
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.